BARDA Award Bavarian Nordic $157M for Smallpox/mpox Vaccine Replenishment

After Jynneos, the smallpox/mpox vaccine, became on sale in early 2024, Bavarian Nordic, a Danish manufacturer, signed a new supply arrangement with the US administration.

In anticipation to the 2022 epidemic of mpox, the illness previously referred to as monkeypox, Bavarian Nordic is receiving a $156.8 million award from the Biomedical Advanced Research and Development Authority (BARDA) to “partly replenish” vaccination supplies.

According to a press statement from the firm, the new supply arrangement is required to complete Bavarian Nordic’s current arrangement with the United States to offer a future, freeze-dried form of its vaccine for smallpox preparation.

As for the shot bulk item, Bavarian Nordic is expected to get $139.7 million for its production and invoicing in 2024. Between 2025 to 2027, the extra $17 million under the agreement will support fresh offerings such as the preservation of vaccine doses in the United States.